For the tumor agnostic accelerated approval, efficacy was shown in 41 patients with RET fusion–positive tumors (other than NSCLC and thyroid cancer) with disease progression on or following prior systemic treatment or who had no satisfactory alternative treatment options. This evidence concerns the gene RET and thyroid cancer.